OTLK Director Sukhtian bought 122,174 shares at $0.41; holdings surge +3593.4%; 3 other insiders bought in past 14 days
Faisal Ghiath Sukhtian purchased 122,174 shares of Outlook Therapeutics at $0.41 on 2026-05-27, expanding his holdings from 3,400 shares to 125,574 shares, a net change of +3593.4% versus pre-transaction holdings. The transaction occurred in a cluster context: 3 other insiders also purchased shares within the past 14 days, suggesting coordinated or independently motivated accumulation at low price levels. The current price of $0.52 reflects a 30-day gain of +82.5%, though the stock remains -84.7% below its 52-week high of $3.39. Against the company's financial backdrop of $1.5M quarterly revenue and $-4.5M net loss in the latest quarter, the multi-insider buying pattern during depressed valuation warrants investor attention to whether insiders see inflection potential or whether the cluster represents passive or scheduled acquisitions.